| MeSH term | MeSH ID | Detail |
|---|---|---|
| Diabetes Mellitus, Type 2 | D003924 | 87 associated lipids |
| Mammary Neoplasms, Experimental | D008325 | 67 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Stomach Neoplasms | D013274 | 24 associated lipids |
| Arthritis | D001168 | 41 associated lipids |
| Surgical Wound Infection | D013530 | 7 associated lipids |
| Abscess | D000038 | 13 associated lipids |
| Acute Kidney Injury | D058186 | 34 associated lipids |
| Gastritis | D005756 | 27 associated lipids |
| Heart Failure | D006333 | 36 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Patel AM et al. | Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study. | 2013 | Ann. Intern. Med. | pmid:23778904 |
| McMahon BJ et al. | The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. | 2003 | Ann. Intern. Med. | pmid:13679322 |
| Sjölund M et al. | Long-term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacter pylori. | 2003 | Ann. Intern. Med. | pmid:13679325 |
| Summaries for patients. Past antibiotic use affects resistance and outcomes of Helicobacter pylori infection. | 2003 | Ann. Intern. Med. | pmid:13679344 | |
| Seow J and Chew FT | Risk factors for Helicobacter pylori resistance. | 2004 | Ann. Intern. Med. | pmid:15172911 |
| Ohkusa T et al. | Disappearance of hyperplastic polyps in the stomach after eradication of Helicobacter pylori. A randomized, clinical trial. | 1998 | Ann. Intern. Med. | pmid:9841603 |
| De Francesco V et al. | Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. | 2006 | Ann. Intern. Med. | pmid:16418408 |
| Yang YJ et al. | Ten days of levofloxacin-containing concomitant therapy can achieve effective Helicobacter pylori eradication in patients with type 2 diabetes. | 2017 | Ann. Med. | pmid:28266875 |
| Trotti LM et al. | Clarithromycin in γ-aminobutyric acid-Related hypersomnolence: A randomized, crossover trial. | 2015 | Ann. Neurol. | pmid:26094838 |
| Ferreri AJ et al. | High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial. | 2015 | Ann. Oncol. | pmid:25935794 |
| Di Raimondo F et al. | Is endoscopic ultrasound clinically useful for follow-up of gastric lymphoma? | 2007 | Ann. Oncol. | pmid:17065587 |
| Rhee CS et al. | Effects of clarithromycin on rheological properties of nasal mucus in patients with chronic sinusitis. | 2000 | Ann. Otol. Rhinol. Laryngol. | pmid:10823478 |
| Heffernan CB et al. | Does Clarithromycin Cause Hearing Loss? A 12-Year Review of Clarithromycin Therapy for Nontuberculous Mycobacterial Lymphadenitis in Children. | 2018 | Ann. Otol. Rhinol. Laryngol. | pmid:30032669 |
| Clifford K et al. | Double-blind comparative trial of ciprofloxacin versus clarithromycin in the treatment of acute bacterial sinusitis. Sinusitis Infection Study Group. | 1999 | Ann. Otol. Rhinol. Laryngol. | pmid:10214783 |
| Mullin D et al. | Mycobacterium chelonae infections involving the head and neck. | 2009 | Ann. Otol. Rhinol. Laryngol. | pmid:19894399 |
| Callaghan R and Allen M | Mycobacterium malmoense infection of the knee. | 2003 | Ann. Rheum. Dis. | pmid:14583565 |
| Hiramatsu M et al. | Risk factors that affect the surgical outcome in the management of focal bronchiectasis in a developed country. | 2012 | Ann. Thorac. Surg. | pmid:22119119 |
| Fan X et al. | Lung perfusion with clarithromycin ameliorates lung function after cardiopulmonary bypass. | 2006 | Ann. Thorac. Surg. | pmid:16488691 |
| Nelson KG et al. | Results of operation in Mycobacterium avium-intracellulare lung disease. | 1998 | Ann. Thorac. Surg. | pmid:9725364 |
| Kadir IS et al. | Recurrent acute rheumatic fever: a forgotten diagnosis? | 2004 | Ann. Thorac. Surg. | pmid:15276555 |
| Bossert T et al. | Successful management of two heart transplant recipients with mycobacterial pulmonary infections. | 2005 | Ann. Thorac. Surg. | pmid:16039241 |
| Watanabe M et al. | Early pulmonary resection for Mycobacterium avium complex lung disease treated with macrolides and quinolones. | 2006 | Ann. Thorac. Surg. | pmid:16731124 |
| Gintovt EA | [Use of clarithromycin in the treatment of atopic dermatitis complicated by staphylococcal infection]. | 2004 | Antibiot. Khimioter. | pmid:15164520 |
| Vasil'ev IuV and Zvenigorodskaia LA | [Fromilide (clarithromycin) in eradication of Helicobacter pylori in patients with duodenal ulcer]. | 2002 | Antibiot. Khimioter. | pmid:12365323 |
| Iakovlev EA et al. | [Present stage of chemotherapy and chemoprophylaxis of rickettsiosis and Q fever]. | 2011 | Antibiot. Khimioter. | pmid:22856156 |
| Iakovlev VP | [New semisynthetic macrolides. Clarithromycin--its importance in the current therapy of bacterial infections]. | 1999 | Antibiot. Khimioter. | pmid:10635418 |
| Evdokimova AG et al. | [New approaches to therapy of Helicobacterpylori infection (by the materials of the Maastricht Consensus-IV, Florence, 2010)]. | 2013 | Antibiot. Khimioter. | pmid:24640139 |
| Iakovlev VP et al. | [Macrolide antibiotic clarithromycin (Klabax) in treatment of community-acquired respiratory tract infections]. | 2000 | Antibiot. Khimioter. | pmid:11210297 |
| Shcherbakov PL | [Clarithromycin in eradication therapy of helicobacter infections in children]. | 2001 | Antibiot. Khimioter. | pmid:11871315 |
| Sazykin IuO et al. | [Clarithromycin and tumor chemotherapy]. | 2000 | Antibiot. Khimioter. | pmid:11210301 |
| Iutanova NS | [Clinical efficacy of clarithromycin delayed release dosage form in the treatment of community-acquired pneumonia]. | 2004 | Antibiot. Khimioter. | pmid:15344392 |
| Budanov SV and Vasil'ev AN | [Clarithromycin: specific features of antimicrobial spectrum and clinical use]. | 2004 | Antibiot. Khimioter. | pmid:15285409 |
| Guchev IA et al. | [Evaluation of clarithromycin efficacy in the treatment of community-acquired pneumonia on the basis of the Binax NOW test results (a prospective open trial)]. | 2002 | Antibiot. Khimioter. | pmid:12619516 |
| Aoki D et al. | Roxithromycin inhibits angiogenesis of human hepatoma cells in vivo by suppressing VEGF production. | Anticancer Res. | pmid:15816530 | |
| Ohara T et al. | Antibiotics directly induce apoptosis in B cell lymphoma cells derived from BALB/c mice. | 2004 Nov-Dec | Anticancer Res. | pmid:15736403 |
| Morikawa K et al. | Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. | 1996 | Antimicrob. Agents Chemother. | pmid:8726002 |
| Endo H et al. | Effects of clarithromycin and amoxicillin on gastric emptying in rats. | 2002 | Antimicrob. Agents Chemother. | pmid:12234874 |
| Hoppe JE and Bryskier A | In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine). | 1998 | Antimicrob. Agents Chemother. | pmid:9559823 |
| Dever LL et al. | Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi. | 1993 | Antimicrob. Agents Chemother. | pmid:8215288 |
| Clark CL et al. | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. | 2007 | Antimicrob. Agents Chemother. | pmid:17876003 |
| Bohnert JA et al. | Novel Piperazine Arylideneimidazolones Inhibit the AcrAB-TolC Pump in Escherichia coli and Simultaneously Act as Fluorescent Membrane Probes in a Combined Real-Time Influx and Efflux Assay. | 2016 | Antimicrob. Agents Chemother. | pmid:26824939 |
| Miltner EC and Bermudez LE | Mycobacterium avium grown in Acanthamoeba castellanii is protected from the effects of antimicrobials. | 2000 | Antimicrob. Agents Chemother. | pmid:10858369 |
| English ML et al. | Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies. | 2012 | Antimicrob. Agents Chemother. | pmid:22290969 |
| Biehle J and Cavalieri SJ | In vitro susceptibility of Mycobacterium kansasii to clarithromycin. | 1992 | Antimicrob. Agents Chemother. | pmid:1416897 |
| Alhajlan M et al. | Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors. | 2013 | Antimicrob. Agents Chemother. | pmid:23545534 |
| Chin NX et al. | Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria. | 1987 | Antimicrob. Agents Chemother. | pmid:2953303 |
| Lee JH et al. | Impact of clarithromycin resistance on eradication of Helicobacter pylori in infected adults. | 2005 | Antimicrob. Agents Chemother. | pmid:15793150 |
| Meyer JM et al. | In vitro synergy testing of clarithromycin and 14-hydroxyclarithromycin with amoxicillin or bismuth subsalicylate against Helicobacter pylori. | 1997 | Antimicrob. Agents Chemother. | pmid:9210696 |
| Skinner PS et al. | A bone marrow-derived murine macrophage model for evaluating efficacy of antimycobacterial drugs under relevant physiological conditions. | 1994 | Antimicrob. Agents Chemother. | pmid:7872747 |
| Zhanel GG and Karlowsky JA | In vitro activity of Iclaprim against respiratory and bacteremic isolates of Streptococcus pneumoniae. | 2009 | Antimicrob. Agents Chemother. | pmid:19139284 |